Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR4 | O00206 | 1/20 | 0.49 |
| ▸ | TLR2 | O60603 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | LTA4H | P09960 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 2/20 | 0.41 |
| ▸ | ACACA | Q13085 | 2/20 | 0.41 |
| ▸ | GRM5 | P41594 | 1/20 | 0.40 |
| ▸ | SYK | P43405 | 1/20 | 0.40 |
| ▸ | MLYCD | O95822 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethyne SCHEMBL27831513 | 0.96 | TLR4 (0.47) | TLR4TLR2PDPK1LTA4HTSHR | |
| SCHEMBL4685740 | 0.96 | TLR4 (0.47) | TLR4TLR2PDPK1LTA4HTSHR | |
| SCHEMBL3407749 | 0.81 | LMNA (0.52) | TLR4TLR2LTA4HHPGDSMN1; SMN2 | |
| Diphenylether SCHEMBL28212638 | 0.81 | TLR4 (0.42) | TLR4TLR2PDPK1LTA4HTSHR | |
| SCHEMBL25369458 | 0.80 | FBP1 (0.43) | TLR4TLR2LTA4HKMT2AMEN1 | |
| SCHEMBL2931895 | 0.80 | TLR4 (0.40) | TLR4TLR2TSHRACACBACACA | |
| SCHEMBL21274270 | 0.80 | L3MBTL1 (0.44) | TLR4TLR2LTA4HKMT2AMEN1 | |
| SCHEMBL1371678 | 0.80 | MEN1 (0.50) | TLR4TLR2LTA4HTSHRKMT2A | |
| SCHEMBL7492368 | 0.80 | TLR4 (0.40) | TLR4TLR2TSHRRAB9AACACB | |
| SCHEMBL4743684 | 0.80 | FBP1 (0.51) | TLR4TLR2LTA4HTSHRKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4619861-A | COATING PARTICLES WITH ORGANONITROGEN OR ORGANOSULFUR POLYMER | TDK CORPORATION (JP) | 1986-10-28 | — | — | US | claimed |
| CN-112996486-A | Local delivery of therapeutic agents comprising cell penetrating peptides for the treatment of age-related macular degeneration and other eye diseases | K·罗伊兹曼 | 2021-06-18 | — | — | CN | disclosed |
| EP-3279187-B1 | 9-MEMBERED FUSED RING DERIVATIVE | SHIONOGI & CO (JP) | 2021-06-02 | — | — | EP | disclosed |
| US-20210138034-A1 | TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES WITH APOLIPOPROTEIN MIMETICS | MACREGEN, INC. (US) | 2021-05-13 | — | — | US | disclosed |
| US-20210085797-A1 | TOPICAL DELIVERY OF THERAPEUTIC AGENTS USING CELL-PENETRATING PEPTIDES FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES | MACREGEN, INC. (US) | 2021-03-25 | — | — | US | disclosed |
| US-10905770-B2 | Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases | MACREGEN, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| CN-107446840-B | 2-phenyl-6-hydroxy-3-pyridazinone degrading bacterium and application thereof | 江苏南资环保科技有限公司 | 2020-07-10 | — | — | CN | disclosed |
| EP-3670496-A2 | ACC2 INHIBITORS | Shionogi&Co., Ltd. (JP) | 2020-06-24 | — | — | EP | disclosed |
| EP-3654941-A1 | TOPICAL DELIVERY OF THERAPEUTIC AGENTS COMPRISING CELL-PENETRATING PEPTIDES FOR USE FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES | Roizman, Keith (US) | 2020-05-27 | — | — | EP | disclosed |
| CN-111153516-A | Treatment process for treating phenylhydrazine hydrochloride wastewater by using macroporous resin | 启东亚太药业有限公司 | 2020-05-15 | — | — | CN | disclosed |
| CN-101973660-A | Recycling and pretreatment methods of raw materials containing benzene thiazole alcohol pesticide industrial wastewater | UNIV ZHEJIANG | 2011-02-16 | — | — | CN | disclosed |
| CN-101973660-A | Recycling and pretreatment methods of raw materials containing benzene thiazole alcohol pesticide industrial wastewater | UNIV ZHEJIANG | 2011-02-16 | — | — | CN | disclosed |
| EP-2166843-A2 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2010-03-31 | — | — | EP | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| WO-2009023059-A2 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2009-02-19 | — | — | WO | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
| US-5670526-A | ANTIINFLAMMATORY AGENT, IMMUNOSUPPRESSANT | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-09-23 | — | — | US | disclosed |
| US-4619861-A | COATING PARTICLES WITH ORGANONITROGEN OR ORGANOSULFUR POLYMER | TDK CORPORATION (JP) | 1986-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | TLR4 4210/4885TLR2 4494/4885PDPK1 705/4885 |
| US-20210085797-A1 | TOPICAL DELIVERY OF THERAPEUTIC AGENTS USING CELL-PENETRATING PEPTIDES FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION AND OTHER EYE DISEASES | NPC1L1, STARD3, CETP | TLR4 1337/4885TLR2 1480/4885PDPK1 391/4885 |
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | TLR4 1172/4885TLR2 1424/4885PDPK1 969/4885 |
| US-10905770-B2 | Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases | NPC1L1, STARD3, CETP | TLR4 1337/4885TLR2 1480/4885PDPK1 391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.